CCI4EU - Molecular diagnostics and precision medicine
MATERIALS AVAILABLE
CCI4EU - Molecular diagnostics and precision medicine
MATERIALS AVAILABLE

Chairs: Anna Sapino, IT - Olli Carpen, FI - Rui Henrique, PT
Target audience
Pathologists, researchers, management, coordinators, patient advocates.
Course delivery
Official language
LIVE STREAMING
Welcome and introduction
Opportunistic genetic screening for breast cancer predisposition
Discussion
Olli Carpén (FI) Minja Pehrsson (FI)Molecular Diagnostics and precision medicine
Molecular Diagnostics: where we are today: aim, techniques
Umberto Malapelle (IT)Molecular Diagnostics: where we are going in the future
Albrecht Stenzinger (DE)Practical Implementations: what is needed, coordination, resources, delivery, budgets, challenges
Discussion
Marius Ilié (FR) Umberto Malapelle (IT) Caterina Marchiò (IT) Albrecht Stenzinger (DE)Molecular Tumour Boards
The Importance of Molecular Tumour Boards
Laura Mezquita (ES)How to create/implement/co-ordinate Molecular Tumour Boards
Rodrigo Dienstmann (ES)Molecular Tumour Boards: Protocols and Regulations
Discussion
Sigmund Brabrand (NO) Gennaro Ciliberto (IT) Rodrigo Dienstmann (ES) Laura Mezquita (ES)BREAK
Financial issues in precision medicine
Case 1 - Example reimbursement model
Bengt Jönsson (SE)Case 2 - Example reimbursement model
Nicola Normanno (IT)Discussion on sustainability: pros, cons and challenges
Bengt Jönsson (SE) Nicola Normanno (IT)Patient advocate
The importance of patient advocates to implement molecular diagnostics and precision medicine
Bettina Ryll (SE)Discussion
Rui Henrique (PT) Bettina Ryll (SE)Clinical Trials in precision medicine
Ongoing clincial trials in place
Åslaug Helland (NO)Future of clinical trials
Vanesa Gregorc (IT)Discussion
Vanesa Gregorc (IT) Åslaug Helland (NO)Closing remarks
Albrecht Stenzinger
Heidelberg University Hospital, , Heidelberg, DE
Anna Sapino
IRCCS Istituto di Candiolo, Dept. of Pathology, Candiolo, IT
Åslaug Helland
Oslo universitetssykehus HF - Oslo University Hospital, Institute of Clinical Medicine, Oslo, NO
Bengt Jönsson
Stockholm School of Economics, Economics Dept., Stockholm, SE
Bettina Ryll
Melanoma Patient Network Europe, Patient Advocacy Dpt., Uppsala, SE
Caterina Marchiò
FPO Istituto di Ricovero e Cura a Carattere Scientifico, Dip. di Scienze Mediche, Candiolo, IT
Gennaro Ciliberto
Istituto Nazionale Tumori Regina Elena, Scientific Directorate, Rome, IT
Laura Mezquita
University of Barcelona, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, ES
Marius Ilié
, , ,
Minja Pehrsson
, , ,
Nicola Normanno
ITN - IRCCS G. Pascale Foundation, Cell Biology and Biotherapy Unit, Napoli, IT
Olli Carpén
University of Helsinki, Department of Pathology, Helsinki, FI
Rodrigo Dienstmann
Vall d’Hebron Institute of Oncology, Molecular Therapeutic Research Unit, Barcelona, ES
Rui Henrique
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Pathological Anatomy Service, Porto, PT
Sigmund Brabrand
, , ,
Umberto Malapelle
University of Naples Federico II, Dpt. of Public Health, NAPOLI, IT
Vanesa Gregorc
Istituto di Candiolo IRCC, Dept. of Oncology, Torino, IT
